Compositions for generating immune tolerance by targeting erythrocytes
AssigneeEcole Polytechnique Federale De Lausanne (Epfl)
InventorsJeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
Life of this patent
Estimating the term…
Abstract
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
Claims21
(canceled)
A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
- an antigen that results in an unwanted immune response upon administration of the antigen to a subject and recognition of the antigen by an immune cell;
- wherein said antigen comprises Factor VIII;
- an erythrocyte-binding moiety,
- wherein said erythrocyte-binding moiety comprises a peptide ligand, an antibody fragment, or a single chain variable fragment derived from an antibody,
- wherein the antigen is fused with the erythrocyte-binding moiety;
- wherein said erythrocyte-binding moiety does not specifically bind to other blood components other than glycophorin-A;
- wherein said composition is suitable for intravenous delivery to the subject;
- wherein said erythrocyte-binding moiety has the ability to non-covalently bind an erythrocyte in situ in blood;
- and
- wherein said binding results in the antigen being presented to the immune system and results in antigen-specific tolerance.
A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
- an antigen selected from the group consisting of Factor VIII and fragments thereof, the antigen being chemically conjugated with at least one erythrocyte-binding moiety, an immune system of the subject being able to respond to or previously having responded to the antigen with an unwanted immune response,
- said erythrocyte-binding moiety having the ability to non-covalently bind an erythrocyte surface in situ in blood and present said antigen to the immune system of the subject as self,
- wherein said erythrocyte-binding moiety comprises a protein or peptide ligand,
- wherein said erythrocyte-binding moiety does not specifically bind to other blood components, and
- wherein the erythrocyte-binding moiety has a dissociation constant of between about 10 μM and 0.1 nM as determined by equilibrium binding measurements between the erythrocyte-binding moiety and erythrocytes.
A composition for immunomodulation to achieve antigen-specific tolerance, the composition comprising:
- an antigen fused or chemically conjugated with an erythrocyte-binding moiety;
- said antigen comprising a therapeutic protein or peptide;
- said antigen being recognizable by an immune system of a subject, the immune system of the subject being able to respond to or previously having responded to the antigen with an unwanted immune response,
- said erythrocyte-binding moiety having the ability to non-covalently, specifically bind an erythrocyte surface in situ in blood and present said antigen to the immune system of the subject, and
- wherein said erythrocyte-binding moiety comprises a peptide, an antibody, or an antibody fragment.
Dependencies are inferred from the claim text.